This message contains images. If you don't see images, click here to view.
Advertise in this news brief.




Text Version   RSS   Subscribe   Unsubscribe   Archive   Media Kit Jan. 15, 2014


 



Obamacare will cover breast cancer prevention drugs
TIME
Costs of breast cancer drugs such as tamoxifen and raloxifene will soon by covered by insurance thanks to the Affordable Care Act, the administration recently announced. The move comes after the U.S. Preventive Services Task Force (USPSTF) — a government-commissioned panel of experts who review all available research on health issues — stated that women who are at a high risk for breast cancer can benefit from taking drugs like tamoxifen and raloxifene to prevent the disease. Based on this conclusion, under the Affordable Care Act, which emphasizes preventive care, these drugs must be covered by insurance with no extra cost to female patients.
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE  


SPONSORED CONTENT


Celebrate World Cancer Day
Union for International Cancer Control
World Cancer Day, sponsored by the Union for International Cancer Control (UICC), will be held on February 4. To help spread the word, the UICC has created a campaign, Debunking Myths about Cancer that can be used to spread the word. The UICC encourages you to to use, adapt, and share the materials to support your activities on that day. Make sure you include your activity on the UICC map of events that is often visited by various media, organizations, and individuals worldwide.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Systemic and comprehensive genomic study of cervical cancer completed
Oncology Nurse Advisor
Researchers from Boston, Mexico, and Norway have completed a comprehensive genomic analysis of cervical cancer in two patient populations. The study identified recurrent genetic mutations not previously found in cervical cancer, including at least one for which targeted treatments have been approved for other forms of cancer. The findings also shed light on the role human papillomavirus plays in the development of cervical cancer.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Ovarian cancer screening has more harms than benefit
Ob.Gyn.News
Ovarian cancer remains the leading cause of death from gynecologic malignancy in the United States. As with other cancers, survival is significantly increased when ovarian cancer is detected at an early stage. For example, for women with stage I cancer the five-year survival rate is 89 percent. The rate is 66 percent for stage II, 34 percent for stage III, and 18 percent for stage IV. Screening methods evaluated include serum tumor markers and ultrasonography. An ovarian cancer symptom index that has been used in combination with tumor markers has been developed. Nevertheless, the current evidence strongly argues against routine screening in average-risk women with CA-125 and/or ultrasonography.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


PRODUCT SHOWCASE
  Special Offer for Readers of The CoC Brief — Practice Review
Are you concerned about diminishing reimbursements? Time to take action and give your practice a check up!
1) Take advantage of the complimentary Practice Analysis.
2) See how you can prepare for the Affordable care Act.
From production and reimbursement to coding and A/R, find out where you are and what you can do to take advantage of the changes in healthcare and to protect your practice.
 


Accreditation 101: Learning the Basics of CoC Accreditation and Standards
Commission on Cancer
Are you a new staff member just learning the ropes of CoC accreditation?
Is your cancer program considering CoC accreditation and you want to learn about the CoC standards?
Do you need a basic refresher on the CoC accreditation process and standards?

If you answered yes to any of these questions, then plan to attend Accreditation 101: Learning the Basics of CoC Accreditation and Standards in Austin, Texas, on Feb. 28. This is the only program developed and taught by CoC surveyors and staff who review the CoC Standards, provide practical information on how to achieve compliance, and discuss the important role you and your cancer team play throughout the continuum of cancer care. Get the information you need from the people involved in standard development and the survey process. For additional information, go to http://www.facs.org/cancer/schedules/accred101.html.

Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


New aspirin-based prodrug may prevent damage caused by chemotherapy
Medical Xpress
Researchers at the University of Georgia (UGA) have developed a new prodrug that promises to reduce many of the negative side effects caused by cisplatin, a commonly prescribed chemotherapy treatment. Cisplatin may be used to treat a variety of cancers, but it is most commonly prescribed for cancer of the bladder, ovaries, cervix, testicles, and lung. It is an effective drug, but it often causes severe and irreversible damage to a patient's kidneys, hearing, and sense of balance. UGA researchers combined cisplatin with aspirin in a new single prodrug formulation they call Platin-A, which prevents these negative side effects by reducing inflammation.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Institutions to share $540 million bequest for cancer research
U-T San Diego
Johns Hopkins University scientists will share in one of the largest one-time philanthropic gifts for cancer research ever made, $540 million aimed at preventing and curing the disease. The $90 million marked for Hopkins Kimmel Cancer Center — among the biggest donations for the center and the university — will help researchers build on pioneering work identifying the genetic mutations responsible for cancers.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


  FEATURED COMPANIES
Advertisement
Oncology OnTrack Supports Nurse Navigation
Oncology OnTrack is used to navigate patients with any cancer type from screening to diagnosis, treatment and survivorship, interfaces with other programs and supports accreditations.
Advertisement
Cancer Registry Impact

Ensure the highest quality oncology data reporting to help improve care and aid in decision making. Learn about Care Communications, Inc. Cancer Registry Services.


Pregnancy exposure to BPA in plastic raises prostate cancer risk
Medical News Today
A study in mice has found prostate cancer is more likely to develop when exposure to BPA levels matches that typical for pregnant women, according to researchers from the University of Illinois at Chicago (UIC) investigating concerns over the chemical used in water bottles. Gail Prins, professor of physiology and director of the andrology laboratory at the UIC College of Medicine, says BPA levels are almost impossible to avoid — the plasticizer is found in water bottles, soup can liners, and paper receipts.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


National Cancer Data Base (NCDB) Call for Data
CoC Source
The official NCDB Call for Data announcement was sent to all programs in a special CoC Source on Oct. 15. The final date for initial submissions is Jan. 31 (midnight Central time), and corrections are due April 1 (midnight Central time). Click "read more" to view the data items required and layout specifications.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Airborne allergies increased risk for hematologic malignancies in women
Healio
Women with a history of airborne allergies, particularly to plants, grass, and trees, were at increased risk for hematologic malignancies, according to results of a population-based study. The association was strongest in certain mature B-cell lymphomas, results showed. “If your immune system is over-reactive, then you have problems; if it’s under-reactive, you’re going to have problems,” study researcher Mazyar Shadman, MD, MPH, senior fellow in the clinical research division at Fred Hutchinson Cancer Research Center in Seattle, Wash., said in a press release.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Novel tomography system may help guide therapy in early breast cancer
OncLive
Diffuse optical tomography is a novel, fast, safe, and low-cost technique that uses near-infrared light to provide three-dimensional data on tissue vascularity without the use of radiation. Columbia University oncologists have been studying whether a system developed at the university can help guide physicians in evaluating chemotherapy and antiangiogenic treatment options for patients with early breast cancer. Andreas H. Hielscher, PhD, a professor of biomedical engineering, electrical engineering, and radiology at Columbia, has designed a digital continuous wave system that images both breasts at the same time at fast-frame rates, with a large number of sources and detectors.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE
 
Advertisement

Advertisement



The CoC Brief

Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Samantha Emerson, Content Editor, 469.420.2669
Contribute news

Disclaimer: The CoC Brief is a digest of the most important news selected for the American College of Surgeons Commission on Cancer from thousands of sources by the editors of MultiBriefs, an independent organization that also manages and sells advertising. The Commission on Cancer does not endorse any of the advertised products and services. Opinions expressed in the articles are those of the author and not of the American College of Surgeons and the Commission on Cancer.


Be sure to add us to your address book or safe sender list so our emails get to your inbox. Learn how.

This edition of The CoC Brief was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!

Recent issues

Jan. 8, 2014
Jan. 2, 2014
Dec. 25, 2013
Dec. 18, 2013






7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063